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Abstract
Background: Loss of heterozygosity (LOH) at chromosome arm 16q is frequently observed in
human breast cancer, suggesting that one or more target tumor suppressor genes (TSGs) are
located there. However, detailed mapping of the smallest region of LOH has not yet resulted in the
identification of a TSG at 16q. Therefore, the present study attempted to identify TSGs using an
approach based on mRNA expression.
Methods: A cDNA microarray for the 16q region was constructed and analyzed using RNA
samples from 39 breast tumors with known LOH status at 16q.
Results:  Five genes were identified to show lower expression in tumors with LOH at 16q
compared to tumors without LOH. The genes for NAD(P)H dehydrogenase quinone (NQO1) and
AT-binding transcription factor 1 (ATBF1) were further investigated given their functions as
potential TSGs. NQO1  has been implicated in carcinogenesis due to its role in quinone
detoxification and in stabilization of p53. One inactive polymorphic variant of NQO1 encodes a
product showing reduced enzymatic activity. However, we did not find preferential targeting of the
active NQO1 allele in tumors with LOH at 16q. Immunohistochemical analysis of 354 invasive breast
tumors revealed that NQO1 protein expression in a subset of breast tumors is higher than in
normal epithelium, which contradicts its proposed role as a tumor suppressor gene.
ATBF1 has been suggested as a target for LOH at 16q in prostate cancer. We analyzed the entire
coding sequence in 48 breast tumors, but did not identify somatic sequence changes. We did find
several in-frame insertions and deletions, two variants of which were reported to be somatic
pathogenic mutations in prostate cancer. Here, we show that these variants are also present in the
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germline in 2.5% of 550 breast cancer patients and 2.9% of 175 healthy controls. This indicates that
the frequency of these variants is not increased in breast cancer patients. Moreover, there is no
preferential LOH of the wildtype allele in breast tumors.
Conclusion: Two likely candidate TSGs at 16q in breast cancer, NQO1 and ATBF1, were identified
here as showing reduced expression in tumors with 16q LOH, but further analysis indicated that
they are not target genes of LOH. Furthermore, our results call into question the validity of the
previously reported pathogenic variants of the ATBF1 gene.
Background
Chromosome arm 16q is one of the regions most fre-
quently involved in loss of heterozygosity (LOH) in breast
cancer [1]. Detailed mapping shows that at least two sep-
arate regions are targeted, implying the presence of more
than one tumor suppressor gene (TSG) [2]. The CDH1
gene, encoding the homotypic adhesion molecule E-cad-
herin and located at 16q22.1, was identified as the target
of LOH at 16q, but gene-truncating mutations were iden-
tified only in the relatively infrequent lobular histological
subtype [3]. CDH1 shows no mutations in tumors with
LOH at 16q of the more common ductal subtype. A few
candidate tumor suppressor genes have been suggested, in
particular CTCF, a gene located at 16q22.1 that encodes
an insulator. Mutations in CTCF have been identified in
breast cancer, but only in a very small subset of cases [4,5].
Mutations in other candidate genes at chromosome 16q
could not be identified, although decreased expression
has been reported for some cases, suggesting that haploin-
sufficiency could be a mechanism of tumorigenesis [6,7].
Thus, the major TSGs at chromosome 16q in ductal breast
cancer remain to be identified [8].
Recently, the gene for AT motif-binding factor 1 (ATBF1)
was reported as a TSG at chromosome arm 16q in prostate
cancer. This designation was based on the fact that ATBF1
is located in the smallest region of overlap affected by loss
of heterozygosity (LOH), and mutations were detected in
prostate cancer cell lines, -xenografts, and -tumors [9].
ATBF1 encodes a transcription factor with four homeobox
domains and 23 Zn-fingers and was first identified as a
suppressor of alpha-fetoprotein transcription [10]. ATBF1
was shown to repress expression of the c-Myb oncogene
[11], and it may activate the cell cycle inhibitor p21 [12].
With the goal of identifying new candidate genes for the
16q TSG, we constructed a cDNA microarray containing
all known and predicted genes at chromosome arm 16q,
and we used it to screen breast tumor RNA for genes that
are down-regulated in tumors with LOH at 16q compared
to tumors without LOH. One of the down-regulated genes
is NQO1, which encodes NAD(P)H dehydrogenase qui-
none 1, a phase II 2-electron reductase that detoxifies
metabolites of benzene and protects the p53 tumor sup-
pressor protein from degradation [13,14].
In this paper, we report the identification of genes at chro-
mosome arm 16q that are significantly down-regulated in
breast tumors with LOH at chromosome 16 using a cDNA
microarray enriched for genes on the long arm of this
chromosome. NQO1 and ATBF1 were identified as the
most promising candidate TSGs. We examined in detail a
polymorphism that affects the stability of the NQO1 pro-
tein in relation to LOH at 16q, but we failed to demon-
strate preferential loss of one specific allele in tumors
showing LOH at 16q. We did observe an association
between NQO1 protein expression and histological grade.
Furthermore, we performed mutational analysis of the
entire open reading frame of the ATBF1 sequence in 48
breast tumors with known LOH status. We found the
same types of sequence variations as previously reported
for prostate cancer [9], but we observed that these varia-
tions are not tumor-specific and that the wild-type allele
is not a specific target of LOH at 16q. This suggests that
some of the previously reported mutations in prostate
cancer may have been erroneously reported as patho-
genic.
Methods
Patient material
RNA for cDNA microarray analysis and quantitative PCR,
and DNA for sequencing and LOH analysis, was isolated
from fresh frozen tumor tissue (n = 39). Prior to RNA/
DNA isolation, H&E sections were evaluated by a pathol-
ogist (VTBHMS) to select tissue blocks with at least 70%
tumor cells. The LOH status at chromosome arm 16q had
previously been determined in detail by using polymor-
phic markers [2]. Characteristics of the 39 tumors used in
this analysis are shown in Table 1. For all tumors, non-
neoplastic DNA from peripheral blood lymphocytes of
the same patients was available. Normal mammary tissue
was obtained from two cosmetic mammary reduction sur-
gery specimens. All specimens were handled according to
the ethical guidelines as described in the 'Code for Proper
Secondary Use of Human Tissue in the Netherlands,' by
the Dutch Federation of Medical Scientific Societies.
DNA from peripheral blood of 541 breast cancer patients
was obtained within the ORIGO project [15]. HealthyBMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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control DNA (n = 172) was isolated from buffy coats
obtained from healthy blood donors.
cDNA microarray analysis with a 16q-specific array
All known transcripts in the 16q21-ter region that were
reported in NCBI, UCSC, Ensembl, and Celera were col-
lected from the Research Genetics sequence verified clone
collection (Invitrogen, The Netherlands), from RZPD
[16], or the Kazusa DNA reagent institute [17], or PCR
amplified from cDNA using gene-specific primers. For
each transcript, at least one cDNA clone was collected,
leading to a total of 702 clones representing approxi-
mately 450 genes. Furthermore, 2000 non-selected cDNA
clones obtained from the Research Genetics sequence ver-
ified clone collection were included for normalization of
the 16q gene expression data. All cDNA clones were
printed on the glass slides at least four times, resulting in
18,026 spots. Microarrays were constructed, hybridized,
and analyzed as described previously [18]. Tumor RNA
was labelled with fluorescein and Cy3, and reference RNA
with biotin and Cy5 using the Micromax TSA Labeling Kit
(Perkin Elmer). The reference RNA consisted of a pool of
equal amounts of RNAs from a panel of cell lines (HL-60,
K562, NCI-H226, COLO205, SNB-19, LOX-IMVI,
OVCAR-3, OVCAR-4, CAK-IPC-3, MCF7, Hs578T,
MCF10F, MCF12A), similar to the panel previously
described [19].
For the identification of differentially expressed genes, R
version 1.9.0 [20] using the Limma package of Bioconduc-
tor [21] was applied as previously described [18].
mRNA expression analysis
For all five genes that showed a significant decrease in
expression in breast tumors with LOH at 16q compared to
breast tumors without LOH, transcript expression was
determined by quantitative reverse transcriptase PCR
(qPCR) on the same RNA used for cDNA microarray anal-
ysis and quantitative RT-PCR as previously described
[18,22]. Briefly, SybrGreen was used to visualize PCR
product formation in real time on a Bio-Rad iCycler (Bio-
Rad, Hercules, CA). The geometric mean of three house-
keeping genes (HNRPM, CPSF6, and TBP) was used to
normalize the expression [22,23]. Primer sequences have
been submitted to the RTPrimerDB (see Availability and
requirements section for URL). Correlation between the
expression levels measured by cDNA microarray and RT-
qPCR was determined using the statistical correlation
function in Microsoft Excel.
Sequencing of ATBF1 in 48 breast tumors
The entire coding sequence of the ATBF1 gene was deter-
mined by generating PCR products using 44 primer pairs,
as previously described [9]. PCR fragments were
sequenced on an ABI 3700 DNA Analyzer. Sequences
were analyzed with Mutation Surveyor™ DNA variant
analysis software version 2.61 (Softgenetics, State College,
PA).
Fragment and LOH analysis
Sequencing resulted in the detection of four polymorphic
repeats, one glutamic acid stretch, and three glutamine
stretches. To analyze the presence of these polymor-
phisms, 20 ng of DNA was PCR amplified using FAM-
labelled primers with the same sequence as the primers
used for DNA sequencing. The fragments were analyzed
on an ABI 3130 genetic analyzer, and the peaks were ana-
lyzed using GeneMapper software version 3.7 (Applied
Biosystems, Foster City, CA).
Table 1: Tumors used for hybridization with a 16q specific cDNA 
array
DNA_No 16q status Grade
BT0374 Retention I
BT0532 Retention II
BT0538 Retention II
BT0642 Retention I
BT0731 Retention III
BT0653 Retention I
BT0681 Retention III
BT0763 Retention II
BT0677 Retention U
BT0602 Retention II
BT0614 Retention II
BT0498 LOH entire 16q II
BT0605 LOH entire 16q I
BT0621 LOH entire 16q I
BT0654 LOH entire 16q I
BT0673 LOH entire 16q I
BT0735 LOH entire 16q I
BT0768 LOH entire 16q II
BT0631 LOH entire 16q U
BT0578 LOH entire 16q II
BT0597 LOH entire 16q II
BT0573 LOH entire 16q III
BT0598 LOH entire 16q II
BT0604 LOH entire 16q II
BT0540 LOH entire 16q I
BT0563 LOH entire 16q I
BT0260 LOH 16q2-ter II
BT0337 LOH 16q2-ter II
BT0509 LOH 16q2-ter III
BT0644 LOH 16q2-ter II
BT0753 LOH 16q2-ter II
BT0193 LOH 16q2-ter U
BT0413 LOH 16q2-ter III
BT0446 LOH 16q2-ter I
BT0559 LOH 16q24 III
BT0757 LOH 16q24 I
BT0410 LOH 16q22 I
BT0505 LOH 16q22 III
BT0335 LOH 16q22 II
U = unknownBMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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LOH at these repeats was analyzed by testing the same
primers on DNA from peripheral blood and breast tumors
of the same patient for those cases that were heterozygous
for a repeat, and by comparing peak ratios as previously
described [2]. The Student's T-test was used to calculate
possible over- or underrepresentation of one of the four
amino acid repeat polymorphisms in breast cancer
patients versus controls.
Immunohistochemical analysis on tissue arrays
A tissue array containing paraffin-embedded formalin
fixed primary breast tumor tissues has been described pre-
viously [24]. Sections of 4 µM were mounted on glass
slides using a PSA® Paraffin Sectioning Kit (Alphelis, Plai-
sir, France), and subsequently stained according to stand-
ard immunohistochemical procedures using citrate
antigen retrieval. The primary antibody recognized NQO1
(A180; Santa Cruz Biotechnology, Santa Cruz, CA), and it
was used at a dilution of 1:1500. Human kidney tissue
was used as a positive control. The staining pattern
observed was identical to that reported previously in kid-
ney podocytes [25]. As a negative control, slides were
incubated with mouse IgG1 antibody, corresponding to
the isotype of the NQO1 antibody.
Stainings were semi-quantitatively scored by two observ-
ers based on visual inspection, and grouped into one of
three categories: complete absence of staining (0), weak
staining (1), or strong staining (2). Statistical analysis of
NQO1 staining was carried out in correlation with other
clinical and histological parameters as reported previously
[24]; these parameters included age, stage, grade, histol-
ogy, lymph node status, status of estrogen and progester-
one receptors, and expression of p53 and HER2/Neu
proteins. Statistical comparisons were made using the
Chi-squared test for comparisons of categorical variables
and ANOVA for continuous variables. All analyses were
performed using SPSS version 12.01 (SPSS Inc, Chicago,
IL). A Bonferroni correction for significance was applied
by dividing the standard significant p-value (0.05) by the
number of different conditions analyzed (n = 9), resulting
in a significance cut-off of p < 0.0055.
Results
Differentially expressed genes in tumors with LOH at 16q 
detected by cDNA microarray analysis
A cDNA microarray was constructed to be highly enriched
for clones representing 450 known and putative genes
from 16q21-16qter which is the region most frequently
affected by LOH. The cDNA microarray contained 702
chromosome 16q specific cDNA clones and 2000 cDNAs
from the entire genome printed in quadruplicate. The
array was hybridized with RNA from 39 breast tumors for
which extensive LOH analysis at 16q had been previously
performed [2]. All tumors were of the ductal subtype, and
their grade and LOH status at 16q are listed in Table 1.
Raw data obtained from the array hybridizations, includ-
ing the list of clones on the micorarray, can be found as
additional file 1 in ref. [26].
After normalization of the data, a Limma analysis was per-
formed to identify genes with differential expression
when comparing tumors with and without LOH at chro-
mosome 16q. The Limma (linear models for microarray
data) package of Bioconductor [21] is a moderated T-sta-
tistic that detects differentially expressed genes between
groups by taking into account the natural variance within
these groups and correcting for false discovery due to mul-
tiple testing. The following genes on chromosome arm
16q were expressed at significantly lower levels (p < 0.05)
in tumors with LOH at 16q compared to tumors without
LOH: NAD(P)H dehydrogenase quinone 1 (NQO1), AT-
binding transcription factor 1 (ATBF1), dysbindin
(DBNDD1), heat shock factor binding protein 1 (HSBP1),
and a brain-specific hypothetical protein (CGI-38). Fig. 1
shows a map of chromosome 16q and the location of
these five genes, with their coordinates as determined on
the UCSC Genome Browser (see Availability and require-
ments for URL).
In order to confirm the cDNA microarray data, quantita-
tive reverse transcriptase PCR (qPCR) was performed on
cDNAs from the same samples that were tested on the
array. Fig. 2 shows the qPCR and microarray data for
NQO1  plotted against each other; the two approaches
show strong correlation of 88%. Correlation for the other
genes was 16% for ATBF1, 80% for HSBP1, 79% for
DNBDD1  and, surprisingly, a negative correlation of -
31% for CGI-38. We also tested whether the expression
level of CDH1, the gene encoding E-cadherin, differed sig-
nificantly between tumors with and without LOH at 16q,
but the was not significant. The correlation between RT-
qPCR and microarray for CDH1 was quite good (88%).
NQO1 and ATBF1 have previously been reported to be
involved in carcinogenesis [9,27], and were therefore
investigated in more depth in breast tumors in this study.
The C609T polymorphism in NQO1
A polymorphism in NQO1 resulting in the amino acid
substitution Pro187Ser has previously been reported to
reduce quinone reductase activity in vitro [28]. We there-
fore investigated the occurrence of this polymorphism in
178 patients with sporadic breast cancer. The results show
that there is no prevalence of the inactive T-allele in this
cohort, since the distribution of C and T (78% and 22%,
respectively) did not differ from the normal distribution
(Table 2) [14]. We hypothesized that if NQO1 is a candi-
date target for LOH at 16q, there should be preferential
loss of the active C-allele in breast cancer. In total, of 60BMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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cases heterozygous for the C609T polymorphism 30% (n
= 18) showed retention of both alleles. Of the remaining
42 cases with LOH, 64% (n = 27) showed LOH of the T-
allele and only 36% (n = 15) showed LOH of the active
allele, which contradicts the hypothesis that LOH at 16q
may be directed at the loss of an active allele of NQO1.
The prevalence for LOH at the inactive allele was not sig-
nificant (p = 0.06).
Finally, we assessed the 16q LOH status of a subset of
cases using polymorphic microsatellite markers as previ-
ously described [8]. Analyzing 30 cases with NQO1 LOH
revealed that also other markers on chromosome arm 16q
show LOH. Remarkably, five cases with 16q retention
showed specific LOH of NQO1: two of these cases showed
LOH of the T-allele, while three showed LOH of the C-
allele.
Tissue array analysis of NQO1 protein expression in breast 
cancer
Protein expression of NQO1 was studied by immunohis-
tochemistry on tissue arrays of invasive breast tumor tis-
sue. In total 354 tumors were successfully examined.
Examples of the staining are shown in Fig 3. Normal
breast epithelium showed no or very weak cytoplasmic
NQO1 staining. In tumors cytoplasmic staining of tumors
varied from entirely absent to strong. A summary of the
results is given in Table 3. Statistical analysis identified a
significant difference (p = 0.005) in NQO1 expression
between grade 1 tumors compared to grade 2 or 3 tumors,
with grade 1 tumors more often showing no or weak
expression (Table 3), similar to normal breast epithelium.
Furthermore, strong NQO1 staining was significantly
associated with positive HER2/Neu protein expression
and positive progesterone receptor (PR) staining. The
association with PR expression, however, was not signifi-
cant when a Bonferroni correction was applied to the p-
value. Other clinical and histological markers were not
associated with NQO1 staining. The patient cohort used
to create the tissue array overlapped minimally with the
cohort for whom the LOH at 16q had been determined.
The status of 16q LOH was known for 13 cases, with nine
showing LOH and four showing retention. However,
there was no significant association between NQO1 status
and LOH at 16q.
DNA sequencing of the entire ATBF1 coding sequence in 
48 breast tumors with known chromosome 16q LOH status
In order to identify somatic mutations in ATBF1 similar to
those reported for prostate cancer [9], we sequenced the
entire coding sequence of the gene using PCR primers as
previously described [9]. The ATBF1  coding sequence
from 43 primary breast tumor samples, selected to con-
tain at least 50% tumor cells, was PCR amplified and
sequenced using the forward PCR primers. This set of
Map of chromosome 16 showing the location of genes down- regulated in breast tumors with LOH at 16q Figure 1
Map of chromosome 16 showing the location of 
genes down-regulated in breast tumors with LOH at 
16q.
HSBP1 (82.4 Mb)
DBNDD1 (88.6 Mb)
ATBF1 (71.4 Mb)
NQO1 (68.3 Mb)
CGI-38 (65.3 Mb)BMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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tumors was enriched for cases with LOH at 16q, only five
cases of which showed 16q retention. Possible sequence
variations were confirmed by sequencing the opposite
strand. The results of all variants for which the sequencing
was consistent in both directions are listed in Table 4.
Most of the variations could be identified as polymor-
phisms, since they were reported as such in either the
ENSEMBL database [29] or by Sun et al. [9]. We detected
five novel single base pair variations that have not previ-
ously been reported, and which therefore may be patho-
genic mutations, however, the same base pair variation
was always detected in germline DNA isolated from non-
neoplastic peripheral blood cells, so they are excluded as
somatic mutations.
Remarkably, we also identified insertions and deletions in
four different amino acid repeats present in this gene
(Table 5). The indels were all in-frame and resulted in a
shorter or longer glutamic acid or glutamine amino acid
repeat. Two of these variants, located in exons 9 and 10,
were reported by Sun et al [9] as somatic pathogenic
mutations in two and nine tumor samples, respectively.
We tested all four insertions/deletions in the correspond-
ing normal DNA, isolated from peripheral blood, and
found that all variants were also present in this non-neo-
plastic tissue. This clearly shows that these variants are not
somatic mutations in breast cancer.
Alternatively, a possible pathogenic nature of the four
amino acid repeat polymorphisms in breast cancer might
be indicated by the detection of preferential loss of the
wildtype allele in tumors. The results are summarized in
Table 5. In total, we identified amino acid polymor-
phisms in 13 out of 116 breast tumor patients, which were
mRNA expression of NQO1 Figure 2
mRNA expression of NQO1. Comparison of NQO1 mRNA expression data assessed bycDNA microarray (y-axis) and 
quantitative reverse transcriptase PCR (x-axis). Microarray data are shown as log10-transformed, normalized ratios; qPCR data 
are shown as the log10-transformed, normalized starting quantities of the mRNA.
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Table 2: NQO1 polymorphism C609T in breast cancer patients
Genotype Nr of breast cancer patients LOH
C/C 109
Retention: 18 (30%)
C/T 60 Loss of C-allele: 15 (25%)
Loss of T-allele: 27 (45%)
T/T 9BMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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selected to show LOH at 16q. In five cases, the wildtype
allele was affected by LOH, whereas in the other eight
cases it was retained and either the variant allele was lost
(n = 6) or there was no LOH (n = 1). This latter case, in
fact, showed LOH only at the most distal part of 16q, a
region that does not contain the ATBF1 gene. The amino
acid length polymorphism in exon 9 was found in only
two samples, and the wild-type allele was lost in both
cases. The other three polymorphisms showed LOH of
both the wildtype and variant alleles.
Furthermore, we tested whether one or more of these var-
iants could confer increased risk of breast cancer by com-
paring their frequency in a population of 550 breast
tumor patients with their frequency in a cohort of 175
healthy controls from the same geographical location. In
total, a variant allele for one of the four polymorphisms
was detected 18 times in 628 successful PCR reactions
(2.9%) in normal controls, whereas a variant allele was
found 49 times in 1961 reactions (2.5%) in the germline
DNA of breast cancer patients. In addition, no significant
difference could be found between the cases and controls
for any of the four separate variants (Table 5).
Discussion
The frequent occurrence of loss of heterozygosity (LOH)
at the long arm of chromosome 16 in breast cancer has led
many investigators to search for the tumor suppressor
genes that may be affected by LOH in this chromosomal
region. Many genes have been proposed as putative candi-
dates. In particular, FBXO31 was recently identified not by
deletion mapping, but by identification of its ability to
induce senescence in tumor cells [7]. However, none of
these genes follow the classical two-hit model of Knudson
[30]. In an attempt to assess all known genes at chromo-
some 16q simultaneously within a single experiment, we
designed a chromosome 16q-specific cDNA microarray
and hybridized the array with RNAs from a series of well-
characterized breast tumors. By comparing tumors with
and without LOH at the 16q arm, we identified a small set
of genes that met our strict statistical standards.
In the present work, we were unable to stratify the groups
based on histological grade or the smallest region of over-
lap involved in LOH, since larger cohorts of patients are
needed for this analysis.
Two genes that showed lower mRNA expression in breast
tumors with LOH at chromosome arm 16q were of partic-
ular interest for breast cancer and were therefore subjected
to more detailed investigation. The most significantly
down-regulated gene was NQO1  encoding NAD(P)H
dehydrogenase quinone 1. This gene has been implicated
in carcinogenesis because of its role in the reduction and
detoxification of quinones and their derivatives, thereby
protecting cells from oxidative damage [14]. Moreover,
NQO1 has been shown to stabilize the p53 tumor sup-
pressor protein by inhibiting its degradation through a
direct protein-protein interaction [13,31]. The possible
role of NQO1 in carcinogenesis has been studied exten-
sively, especially the occurrence of a frequent polymor-
phism, 609C>T, which results in a proline to serine
substitution at amino acid 187 [32]. This substitution
results in a variant with poor enzymatic activity and no
detectable protein, as shown in individuals homozygous
for the T-allele [33]. The prevalence of the 609T allele of
NQO1 has been studied in tumors of lung, bladder, and
colorectal cancer as well as leukaemia. However, the
results are inconsistent [14] and no correlation between
NQO1  allele frequency and breast cancer has been
observed [32,34]. This is consistent with our findings. To
our knowledge there are no studies examining the prefer-
ential loss of heterozygosity of the active 609C allele. A
possible role for NQO1 in breast cancer would be con-
firmed if it could be shown that LOH at 16q is targeted at
the active allele. However, we could not show a preva-
lence of 609C loss and, in fact, LOH was higher at the
609T allele. It is therefore unlikely that NQO1 is the target
tumor suppressor gene at 16q. Nevertheless, the high inci-
dence of LOH (70%) at this locus suggests that the gene
lies near another target gene.
We also investigated NQO1 protein expression in 354
breast tumors. Normal breast epithelium showed no or
only weak expression of this protein, whereas 20% of
breast tumors showed strong staining. This is not consist-
ent with a tumor suppressor function for NQO1. Remark-
ably, intermediate and poorly differentiated tumors
(grade 2 and 3) showed overexpression of NQO1 protein
more often than those showing low differentiation (grade
1). We have previously shown that grade 1 tumors have
LOH at 16q through physical loss, whereas poorly differ-
entiated breast tumors show 16q LOH through mitotic
Table 3: NQO1 immunohistochemical results
NQO1 score nr cases
0 (negative) 152 (43%)
1 (weak) 132 (37%)
2 (strong) 70 (20%)
total 354
Grade 1 Grade 2 or 3 p-value
0 or 1 97 (35%) 179 (65%) 0.005
2 12 (18%) 56 (82%)
HER2-negative HER2-positive
0 or 1 218 (82%) 48 (18%) 0.005
2 43 (66.2%) 22 (34%)
PR-negative PR-positive
0 or 1 134 (49%) 137 (51%) 0.024*
2 44 (65%) 24 (35%)
* not significant after Bonferroni correctionBMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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recombination [35]. Therefore, the absence of NQO1
expression may be attributed to physical loss of 16q and
LOH at 16q may not be specifically targeted at the NQO1
gene. In addition, the expression of HER2  and  NQO1
showed significant correlation. Like NQO1, also HER2
overexpression was more prevalent in poorly differenti-
ated breast tumors, which could explain this correlation.
ATBF1  was an other candidate gene identified by our
microarray analysis showing decreased mRNA expression
in tumors with LOH at 16q. This gene was recently
reported to contain somatic mutations in prostate cancer,
a tumor type in which frequent LOH at 16q is also a hall-
mark [9]. ATBF1 is one of the largest transcription factors
known, containing four homeodomains and 23 zinc fin-
gers [10]. Nevertheless, little is known about its function.
The ATBF1 protein binds to the AT motif of the alpha-feto-
protein (AFP) gene, thereby inhibiting its transcription. A
possible role in tumorigenesis has been found in AFP-pro-
ducing gastric cancer, an aggressive tumor type that lacks
ATBF1 [36]. Interestingly, ATBF1 was found to bind to
Myb oncoprotein, as well as to inhibit transcription of the
MYB  gene [11]. Combined with the identification of
somatic mutations in prostate cancer [9] these features are
consistent with a tumor suppressor function for ATBF1. It
has been suggested that in breast cancer, higher mRNA
expression of ATBF1 is associated with a better prognosis,
i.e. absence of tumor-positive lymph nodes [37]. In a pre-
Immunohistochemical staining for NQO1 Figure 3
Immunohistochemical staining for NQO1. A, normal, negative epithelium; B, negative tumor (0); C, weakly positive 
tumor (1); D, positive tumor (2).BMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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vious study of 712 breast tumors we analyzed a possible
association between positive lymph nodes and LOH sta-
tus at 16q [8], however, we failed to demonstrate a signif-
icant correlation. Since a decrease in mRNA is associated
with 16q LOH, but lymph node status is not, our current
study cannot support the observation by Zhang et al. that
ATBF1 expression is correlated with better prognosis in
breast cancer [37].
Screening of the entire ATBF1 open reading frame of 43
breast tumor DNAs by direct sequencing revealed no
somatic mutations, only previously described single
nucleotide polymorphisms (SNP) and 7 seven new SNPs.
All of these SNPs were also present in matched normal
DNA. Although we cannot exclude that these variants are
pathogenic, this seems quite unlikely because linkage of
Table 4: Variants identified in ATBF1 in 48 breast cancer samples
Nucleotide change Aminoacid change Polymorphism because
Synonymous polymorphisms
1012C>T 113Ala Found multiple times (7/48)
1096A>G 141Ala Reported in Ensembl as polymorphism
2443G>A 590Phe Reported in Ensembl as polymorphism
2497T>C 608Ser Reported by Sun et al. as polymorphism
3058C>G 795Pro Reported in Ensembl as polymorphism
3340C>T 889Ser Reported in Ensembl as polymorphism
3589G>A 972Ser Reported in Ensembl as polymorphism
4018C>T 1115Ser Also present in normal matched sample
4297G>T 1208Ser Also present in normal matched sample
4756C>T 1361Ile Reported in Ensembl as polymorphism
5119A>T 1482Ala Reported in Ensembl as polymorphism
6292C>T 1873His Reported in Ensembl as polymorphism
6829G>A 2052Pro Also present in normal matched sample
7714A>G 2347Gln Reported in Ensembl as polymorphism
7828G>A 2385Pro Reported by Sun et al. as polymorphism
8851T>C 2726Leu Reported in Ensembl as polymorphism
9496A>G 2941Gly Reported in Ensembl as polymorphism
10552C>T 3293Ala Reported in Ensembl as polymorphism
Non-synonymous polymorphism
858C>T Ala62Val Also present in normal matched sample
887A>C Ser72Ala Reported in Ensembl as polymorphism
2053C>G Glu460Gln Reported in Ensembl as polymorphism
2304C>T Ser544Leu Also present in normal matched sample
3003A>G Val777Ala Reported in Ensembl as polymorphism
3515G>A Ala948Ile Also present in normal matched sample
3662G>T Ala997Ser Reported in Ensembl as polymorphism
6143C>G Leu1824Val Reported by Sun et al. as polymorphism
6715G>C Gln2014His Reported by Sun et al. as polymorphism
Table 5: Aminoacid repeat length variations in ATBF1
Exon nr AA position AA Repeat Nature – frequency In tumors* Allele loss In normals In BC patients**
2 487 Glu 15 bp del – 1 4/116 (3.4%) 1 wt 1/172 (0.6%) 7/541 (1.3%)
12 bp ins – 11 2 variants
1 no loss
9 1741 Gln 3 bp del – 1 2/110 (1.8%) 2 wt 5/162 (3.1%) 11/539 (2.0%)
6 bp del – 4
3 bp ins – 4
6 bp ins – 10
10 3202 Gln 21 bp del – 8 1/98 (1%) 1 variant 1/146 (0.7%) 6/530 (1.1%)
10 3380 Gln 3 bp del – 5 6/115 (5.2%) 2 wt 11/148 (7.4%) 27/351 (7.7%)
6 bp del – 15 4 Variants
3 bp ins – 24
* All normal DNAs of these patients show the same variant.
** Tested on normal DNA from peripheral blood cellsBMC Cancer 2008, 8:105 http://www.biomedcentral.com/1471-2407/8/105
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chromosome arm 16q and hereditary breast cancer has
never been demonstrated [38].
We confirmed the same in-frame deletions in contiguous
stretches of glutamic acid codons in exons 9 and 10 as
described by Sun et al. [9] in prostate cancer. However,
whereas those authors reported that these mutations were
somatic, we have shown here that they were also present
in matched normal DNA from peripheral blood cells,
confirming these variants as germline. In addition we
identified similar germline variations at two different
locations in the gene that affect the amino acid repeat
length of stretches of glutamine and glutamic acid resi-
dues. As in the case of the NQO1 polymorphism we could
not show neither preferential LOH of these repeats nor a
possible role in predisposing towards breast carcinogene-
sis. According to our results these repeat length variations
should be considered as polymorphic variations. The
effect of these variations should be further investigated
using functional assays. A dramatic effect is not very likely
given the fact that the variations are bidirectional: both
insertions and deletions were observed in three of four
variants. Recently Xu and co-workers [39] reported a 21-
or 24-nucleotide deletion at position 3381 in ATBF1 in
the germline of prostate cancer patients and concluded
that these variants are associated with prostate cancer risk.
We also found deletions at the same glutamine tract, but
they were only three or six base pairs in length and they
showed no significant difference in frequency between
breast cancer patients and normal controls.
The large number of variations found in ATBF1 can be
explained by the size of the gene, which is exceptionally
large, with over 11 kb of coding sequence. The presence of
simple sequence repeats coding for amino acid repeats
ranging from 8 to 26 residues may explain the high fre-
quency of length variations. Repeat length variations can
lead to pathogenic traits, often neurological in character.
However, these variations are almost invariably expan-
sions that increase over time [40]. All repeats detected in
ATBF1  showed the same length in tumor and normal
DNA, and were in some cases even shorter than the most
frequent allele (Table 3). A recently published study
described the sequencing of the ATBF1  open reading
frame in 32 breast cancer cell lines [41]. Two possible
mutations were identified, one as an amino acid substitu-
tion at codon 2622 and one undefined change in a
poly(T) tract. Whether these mutations were pathogenic
was not verified.
Three other genes were identified to have a significantly
lower expression in breast tumors with LOH at chromo-
some 16q compared to tumors without LOH. The differ-
ence in expression level for one of these, CGI-38, a brain-
specific transcript of unknown function, could not be con-
firmed by RT-qPCR. Expression levels of the other two,
dysbindin domain containing 1 (DBNDD1) and heat
shock binding protein 1 (HSBP1) could be confirmed by
RT-qPCR and may be the subject of future breast cancer
research.
Conclusion
Using a chromosome 16q-specific cDNA array to identify
tumor suppressor genes we have found five candidates, of
which the two most interesting, NQO1 and ATBF1, were
excluded as classical candidate genes. Of special note are
our results indicating that ATBF1 variants showing differ-
ences in the length of amino acid repeat sequences are
most likely non-pathogenic and instead are normally
occurring polymorphisms. This calls into question the
conclusions of Sun et al. [9], who found these variants to
be somatic mutations involved in prostate cancer.
New views on the role of loss of heterozygosity in cancer
are currently of importance for their relevance to the tar-
geting of multiple genes [42,43] and haploinsuffiency
[44]. These views promise to provide better working
hypotheses for elucidating somatic cancer genetics than
Knudson's two-hit model.
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